Sonnet Biotherapeutics Holdings IncNASDAQ:SONN
- LAST PRICE1.8450
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 1.8450
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SONN |
|---|---|---|
| 09:32 ET | 165 | 1.79 |
| 09:39 ET | 140 | 1.7997 |
| 11:04 ET | 2760 | 1.7899 |
| 01:46 ET | 116 | 1.77 |
| 01:50 ET | 200 | 1.7674 |
| 02:47 ET | 100 | 1.76 |
| 03:09 ET | 697 | 1.7501 |
| 03:16 ET | 600 | 1.79 |
| 03:38 ET | 100 | 1.8014 |
| 03:52 ET | 500 | 1.845 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Sonnet Biotherapeutics Holdings Inc | 5.5M | -0.1x | --- |
Titan Pharmaceuticals Inc | 6.4M | -0.9x | --- |
Hoth Therapeutics Inc | 5.8M | -0.5x | --- |
Eastgate Biotech Corp | 5.7M | -1.6x | --- |
Gold River Productions Inc | 5.3M | 0.0x | --- |
GT Biopharma Inc | 5.0M | -0.7x | --- |
Company Information
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company. The Company's technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The Company designed the FHAB construct to improve drug accumulation in cancer tumors, as well as to extend the duration of activity in the body. Its lead asset, SON-1010, is a fully human single-chain version of Interleukin 12 (IL-12), covalently linked to the FHAB construct, for which it is pursuing clinical development in solid tumors. Its lead clinical-stage asset, SON-080, is a fully human version of IL-6 manufactured in Chinese Hamster Ovary (CHO) cells. SON-080, for its target indications of Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN). Its pipeline also includes SON-1210, SON-1410 and SON-3015.
Contact Information
- Headquarters
- 100 Overlook Center, Suite 102PRINCETON, NJ, United States 08540
- Phone
- 609-375-2227
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer
- Pankaj Mohan
- Chief Financial Officer
- John Cross
- Chief Scientific Officer
- John Cini
- Chief Technical Officer
- Susan Dexter
- Chief Medical Officer
- Richard Kenney
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.7M |
|---|---|
Revenue (TTM) | $129.2K |
Shares Outstanding | 3.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.62 |
EPS | $-12.91 |
Book Value | $-0.13 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 43.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -11,192.10% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
